Polaris Pharmaceuticals
Richard E. Showalter has a diverse work experience spanning over several decades. Richard E. began their career as a Research Associate at the Agouron Institute in 1984, where they contributed to the development of molecular genetic tools and made significant discoveries in bacterial communication and potential antibacterial agents. In 1992, they joined the California Department of Justice as a Criminalist-DNA Crime Lab, specializing in forensic DNA analysis and providing support for the development of a DNA database. Moving into the pharmaceutical industry, Showalter worked as a Research Scientist II at Agouron Pharmaceuticals/Warner Lambert/Pfizer from 1993 to 2001, focusing on drug discovery in various therapeutic areas and leading projects in neurodegenerative diseases. Richard E. then joined Anadys Pharmaceuticals/Roche as an Associate Research Fellow, where they played a crucial role in drug discovery projects, protein engineering, and project leadership. Since 2012, Showalter has been associated with Polaris Pharmaceuticals, where they initially served as a Senior Research Fellow in Structural Biology before progressing to the role of Executive Director, Discovery Research. Currently, they hold the position of Vice President of Research and Development at Polaris Pharmaceuticals. Throughout their career, Showalter has demonstrated a strong expertise in research and development, project leadership, and drug discovery across different industries and organizations.
Richard E. Showalter's education history includes a Certificate in Forensic Science and Technology from the California Criminalistics Institute, which they obtained from 1992 to 1993. Prior to that, from 1983 to 1984, they received a Certificate in Recombinant DNA Techniques from San Diego State University. Richard E.'searliest education experience was at UC San Diego, where they pursued a Bachelor of Arts (B.A.) degree in Biochemistry and Molecular Biology from 1978 to 1983.
Polaris Pharmaceuticals
Polaris Group, a privately held multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases in humans. Polaris' lead project is ADI-PEG 20, a biotherapeutic agent that is in advanced clinical development for the treatment of hepatocellular carcinoma and metastatic melanoma. Polaris is collaborating with EnzymeRx in the development of Uricase-PEG 20 for the treatment of gout, tumor lysis syndrome, and other diseases related to hyperuricemia. Polaris is also researching and developing other biotherapeutic agents and has a small molecule drug program. The latter utilizes a rational structure-based approach for the design of novel compounds that inhibit the biological function of cancer-related protein targets.